Shares of Shield Therapeutics plc (LON:STX – Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 6.27 and traded as low as GBX 6. Shield Therapeutics shares last traded at GBX 6.50, with a volume of 575,290 shares traded.
Shield Therapeutics Trading Up 4.0%
The company has a market cap of £69.52 million, a P/E ratio of -3.25 and a beta of 1.76. The business has a fifty day moving average price of GBX 6.27 and a 200-day moving average price of GBX 8.33. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
